

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT6377089

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
GLAXOSMITHKLINE AUSTRALIA PTY LIMITED	08/31/2015
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	SUN PHARMACEUTICAL INDUSTRIES (AUSTRALIA) PTY LTD
<b>Street Address:</b>	LEVEL 4, 1 ACACIA PLACE
<b>City:</b>	NOTTING HILL, VIC
<b>State/Country:</b>	AUSTRALIA
<b>Postal Code:</b>	3168
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	17084878
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(503)595-5301
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	503-595-5300
<b>Email:</b>	deborah.martin@klarquist.com
<b>Correspondent Name:</b>	SHEREE L. RYBAK, PH.D./KLARQUIST SPARKMAN, LLP
<b>Address Line 1:</b>	121 SW SALMON STREET
<b>Address Line 2:</b>	ONE WORLD TRADE CENTER, SUITE 1600
<b>Address Line 4:</b>	PORTLAND, OREGON 97204-2988
<b>ATTORNEY DOCKET NUMBER:</b>	8617-90202-05
<b>NAME OF SUBMITTER:</b>	SHEREE LYNN RYBAK, PH.D.
<b>SIGNATURE:</b>	/Sheree Lynn Rybak/
<b>DATE SIGNED:</b>	10/30/2020
<b>Total Attachments: 4</b>	
source=Assignment (GSK to Sun Pharmaceuticals)#page1.tif	
source=Assignment (GSK to Sun Pharmaceuticals)#page2.tif	
source=Assignment (GSK to Sun Pharmaceuticals)#page3.tif	
source=Assignment (GSK to Sun Pharmaceuticals)#page4.tif	

## Deed of Confirmation of Assignment of Patents

This Deed is made on 31 August 2015.

### Parties

- 1 GlaxoSmithKline Australia Pty Ltd ABN 47 100 162 481 of 1061 Mountain Highway, Boronia, Victoria 3155 (the *Vendor*).
- 2 Sun Pharmaceutical Industries (Australia) Pty Ltd ABN 64 130 119 603 of C/- Baker & McKenzie, Level 19, CBW, 181 William Street, Melbourne, Victoria 3000 (the *Purchaser*).

### Recitals

- A The Vendor is the registered proprietor of the United States of America (*USA*) patents and patent applications listed in the Schedule (*Patents*).
- B The Vendor agreed to assign to the Purchaser all its right, title and interest in and to the Patents on the terms set out in the Business Sale Agreement dated 3 March 2015 between the Vendor and the Purchaser (*Business Sale Agreement*).
- C This Deed confirms the assignment of the Patents effected by the Business Sale Agreement.

It is agreed as follows.

#### 1 Assignment

The Vendor and the Purchaser hereby confirm that, pursuant to the Business Sale Agreement, with effect from the date of this Deed, the Vendor has assigned to the Purchaser all its right, title and interest in and to the Patents free from any encumbrance, and the Purchaser has accepted that assignment.

#### 2 Further assurances

At the request of the other party, each party undertakes to do anything (including executing agreements and documents) necessary or desirable to give full effect to this Deed and the transactions contemplated by it, including, without limitation, enabling the Purchaser to become registered as the proprietor of the Patents.

#### 3 Governing Law and Jurisdiction

This Deed is governed by the laws of Victoria, Australia. In relation to it and related non-contractual matters, each party irrevocably submits to the non-exclusive jurisdiction of courts with jurisdiction there, and waives any right to object to the venue on any ground.

#### 4 Enurement

The provisions of this Deed will enure for the benefit of, and be binding on, the parties and their respective successors and permitted substitutes and assigns and (where applicable) legal personal representatives.

#### 5 Amendment

No amendment or variation of this Deed is valid or binding on a party unless made in writing executed by all parties.


**6 Counterparts**

This Deed may be executed in any number of counterparts. All counterparts together will be taken to constitute one instrument.

Executed and Delivered as a Deed in Melbourne, Victoria.

Executed in accordance with section 127 of the *Corporations Act 2001* by  
GlaxoSmithKline Australia Pty Ltd:

  
\_\_\_\_\_  
Director Signature  
**Geoff McDonald**  
\_\_\_\_\_  
Print Name VP & General Manager, Australia

  
\_\_\_\_\_  
Director/Secretary Signature  
**Johann Fatscher**  
\_\_\_\_\_  
Print Name

Executed in accordance with section 127 of the *Corporations Act 2001* by Sun  
Pharmaceutical Industries (Australia) Pty Ltd:

\_\_\_\_\_  
Director Signature  
  
\_\_\_\_\_  
Print Name

\_\_\_\_\_  
Director/Secretary Signature  
  
\_\_\_\_\_  
Print Name

**6 Counterparts**

This Deed may be executed in any number of counterparts. All counterparts together will be taken to constitute one instrument.

Executed and Delivered as a Deed in Melbourne, Victoria.

Executed in accordance with section 127 of  
the *Corporations Act 2001* by  
GlaxoSmithKline Australia Pty Ltd:


.....  
Director Signature

.....  
Director/Secretary Signature

.....  
Print Name

.....  
Print Name

Executed in accordance with section 127 of  
the *Corporations Act 2001* by Sun  
Pharmaceutical Industries (Australia) Pty  
Ltd:

  
.....  
Director Signature

  
.....  
Director/Secretary Signature

G. A. ZIREC  
.....  
Print Name

Guido Stracke  
.....  
Print Name

**Schedule - Patents (USA)**

TITLE	APPLICATION NUMBER	PATENT NUMBER	STATUS	GRANT DATE	REGISTERED OWNER
Methods of altering poppy characteristics	12/064429	8557737	Granted	15-Oct-2013	GlaxoSmithKline Australia Pty Ltd
Method of altering the alkaloid composition in poppy plants	11/568651	8377851	Granted	19-Feb-2013	GlaxoSmithKline Australia Pty Ltd
Methyltransferase nucleic acids and polypeptides	13/806310	-	Filed	-	GlaxoSmithKline Australia Pty Ltd
Plant Cytochrome P450	13/808608	-	Allowed	-	GlaxoSmithKline Australia Pty Ltd
Nucleic Acid Molecule	14/375120		Filed		GlaxoSmithKline Australia Pty Ltd